Alterações fisiológicas e efeitos sedativos da associação entre buprenorfina e xilazina em equinos

Detalhes bibliográficos
Autor(a) principal: Cruz, Fernando Silvério Ferreira da
Data de Publicação: 2008
Tipo de documento: Dissertação
Idioma: por
Título da fonte: Biblioteca Digital de Teses e Dissertações do UFSM
Texto Completo: http://repositorio.ufsm.br/handle/1/8938
Resumo: The α₂-adrenergic receptor agonists are widely used in equine practice, especially in antalgic therapy, because they promote profound sedation and moderate visceral analgesia. The opioids are used in horses with some restriction due to the excitatory effects in this specie. The objective of this study was to evaluate the sedative effect, hemodynamic, pulmonary and digestory changes due to the neuroleptoanalgesic association of buprenorphine and different doses of xylazine. Six adults horses of both gender, weighting an average of 400 Kg. The animals were control of themselves, being divided into four groups, control group (CG) saline NaCl 0,9% solution administrated IV, and three other groups with buprenorphine 10 μg/kg associated to three different doses of xylazine, 0,25 mg/kg (BX25), 0,50 mg/kg (BX50) and 0,75 mg/kg (BX75) IV. Sedative effects, gastrointestinal motility, FC, f, SAP, MAP, DAP, blood gas tension analysis and core temperature were evaluated 30 min before, immediately before the administration of any treatment for basal values and after 5, 15 and every 15 min until 120 min post-treatment. Gastrointestinal motility was evaluated by the same period and for 12 hours, every 2 hours. Blood samples were collected at 0, 30 and 60 min. Parametric variables were analyzed with ANOVA, followed by Dunnett test for intra group and Tukey test between groups. For the non-parametric variable (intestinal motility) Wilcoxon test was used. Differences was considered significant when P<0.05. Intense sedative effect was observed in the three groups with the neuroleptoanalgesic association lasting 45 min in BX75 with profound ataxia. Intestinal motility decreased with 5 minutes after administration and remained decreased for 8 hours. Hemodynamic parameters started to increased after 30 min and no changes were observed in respiratory frequency and blood gas samples analysis, only HCO3- showed increase. Synergistic effect was observed, maintaining hemodynamic stability, with minimal pulmonary effects. The hypomotility observed must be considered when the association is used in horses with gastrointestinal disorders.
id UFSM_135d444ab97ae47e0d4b69f4d51b6c6b
oai_identifier_str oai:repositorio.ufsm.br:1/8938
network_acronym_str UFSM
network_name_str Biblioteca Digital de Teses e Dissertações do UFSM
repository_id_str
spelling 2009-03-092009-03-092008-08-08CRUZ, Fernando Silvério Ferreira da. Physiological changes and sedative effects of the association between buprenorphine and xylazine in horses. 2008. 78 f. Dissertação (Mestrado em Farmácia) - Universidade Federal de Santa Maria, Santa Maria, 2008.http://repositorio.ufsm.br/handle/1/8938The α₂-adrenergic receptor agonists are widely used in equine practice, especially in antalgic therapy, because they promote profound sedation and moderate visceral analgesia. The opioids are used in horses with some restriction due to the excitatory effects in this specie. The objective of this study was to evaluate the sedative effect, hemodynamic, pulmonary and digestory changes due to the neuroleptoanalgesic association of buprenorphine and different doses of xylazine. Six adults horses of both gender, weighting an average of 400 Kg. The animals were control of themselves, being divided into four groups, control group (CG) saline NaCl 0,9% solution administrated IV, and three other groups with buprenorphine 10 μg/kg associated to three different doses of xylazine, 0,25 mg/kg (BX25), 0,50 mg/kg (BX50) and 0,75 mg/kg (BX75) IV. Sedative effects, gastrointestinal motility, FC, f, SAP, MAP, DAP, blood gas tension analysis and core temperature were evaluated 30 min before, immediately before the administration of any treatment for basal values and after 5, 15 and every 15 min until 120 min post-treatment. Gastrointestinal motility was evaluated by the same period and for 12 hours, every 2 hours. Blood samples were collected at 0, 30 and 60 min. Parametric variables were analyzed with ANOVA, followed by Dunnett test for intra group and Tukey test between groups. For the non-parametric variable (intestinal motility) Wilcoxon test was used. Differences was considered significant when P<0.05. Intense sedative effect was observed in the three groups with the neuroleptoanalgesic association lasting 45 min in BX75 with profound ataxia. Intestinal motility decreased with 5 minutes after administration and remained decreased for 8 hours. Hemodynamic parameters started to increased after 30 min and no changes were observed in respiratory frequency and blood gas samples analysis, only HCO3- showed increase. Synergistic effect was observed, maintaining hemodynamic stability, with minimal pulmonary effects. The hypomotility observed must be considered when the association is used in horses with gastrointestinal disorders.Os agonistas α₂-adrenérgicos são amplamente empregados na clínica equina, destacando-se na terapia antálgica pela intensa sedação e por produzirem moderada analgesia visceral. Os opióides, apesar de serem utilizados na terapia antálgica de equinos, parecem ainda ter seu uso relativamente restrito, principalmente pela excitação observada quando da utilização destes. O estudo teve como objetivo investigar o efeito sedativo e as alterações hemodinâmicas, pulmonares e digestória decorrentes da utilização da associação neuroleptoanalgésica entre a buprenorfina e diferentes doses de xilazina. Utilizou-se 6 equinos de ambos os sexos, com média de peso de 400kg. Os animais foram divididos em quatro grupos autocontrole, sendo grupo controle, administração de solução fisiológica 0,9% IV, e outros três grupos, com a associação de buprenorfina 10 μg/kg associada a diferentes doses de xilazina, 0,25 mg/kg (BX25), 0,5 mg/kg (BX50) e 0,75 mg/kg (BX75) IV. Avaliouse a atividade sedativa, motilidade intestinal, FC, f, PAS, PAM, PAD, parâmetros hemogasométricos e temperatura corpórea aos 30 min antes, imediatamente antes da administração de qualquer substância para determinação dos valores basais e aos 5min, 15 min, e a cada 15 min até 120 min após o tratamento. A motilidade intestinal foi avaliada pelo mesmo período nos mesmos tempos e a cada duas horas até 12 horas após a administração. Os parâmetros hemogasométricos foram avaliados aos 0, 30 e 60 min. Para as variáveis paramétricas utilizou-se análise de variância para amostras pareadas, com posterior teste de Dunnett. Para comparações entre os grupos, realizou-se análise de variância, seguido de teste de Tukey. Para a variável não-paramétrica, motilidade intestinal, utilizou-se teste de Wilcoxon para amostras pareadas. As diferenças foram consideradas significantes quando P<0,05. Foi observado efeito sedativo significante nos três grupos com a associação neuroleptoanalgésica, perdurando por até 45 min no BX75 com severa ataxia. Observou-se hipomotilidade 5 minutos após a administração perdurando por 480 min. Os parâmetros hemodinâmicos elevaram-se após os 45 min, não sendo observadas alterações na frequência respiratória e nos parâmetros hemogasométricos, ocorrendo aumento somente no HCO3-. Conclui-se que houve efeito sinérgico entre os dois fármacos, mantendo estabilidade hemodinâmica, com mínimas alterações pulmonares. A hipomotilidade promovida pela associação deve ser considerada quando usada em equinos com distúrbios gastrintestinais.application/pdfporUniversidade Federal de Santa MariaPrograma de Pós-Graduação em FarmacologiaUFSMBRFarmacologiaXilazinaBuprenorfinaEquinosSedaçãoAnalgesiaXylazineBuprenorphineHorsesSedationAnalgesiaCNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIAAlterações fisiológicas e efeitos sedativos da associação entre buprenorfina e xilazina em equinosPhysiological changes and sedative effects of the association between buprenorphine and xylazine in horsesinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisCarregaro, Adriano Bonfimhttp://lattes.cnpq.br/5041153897534751Corte, Flavio Desessards de Lahttp://lattes.cnpq.br/4040388452531898Queiroz Neto, Antonio dehttp://lattes.cnpq.br/6695662273447490http://lattes.cnpq.br/4262392857518163Cruz, Fernando Silvério Ferreira da201000000000400500300500300a0421801-2f7d-45b2-a7fb-c0b089433af7e3ab06bd-3d28-4b33-a997-93ba02edaec5ab8aec2d-f3fe-45a4-8bc3-07256644578f19e8f84b-7ad7-4606-973b-baf5993524dbinfo:eu-repo/semantics/openAccessreponame:Biblioteca Digital de Teses e Dissertações do UFSMinstname:Universidade Federal de Santa Maria (UFSM)instacron:UFSMORIGINALDIS_PPGFARMACOLOGIA_2008_CRUZ_FERNANDO.pdfDissertação de Mestradoapplication/pdf1155142http://repositorio.ufsm.br/bitstream/1/8938/1/DIS_PPGFARMACOLOGIA_2008_CRUZ_FERNANDO.pdf3e604c1ba91c9deddf24078cec533efaMD51TEXTFERNANDOSILVERIOFERREIRADACRUZ.pdf.txtFERNANDOSILVERIOFERREIRADACRUZ.pdf.txtExtracted texttext/plain126181http://repositorio.ufsm.br/bitstream/1/8938/2/FERNANDOSILVERIOFERREIRADACRUZ.pdf.txtc079ba0edf55cd3487bf2dd8cb441a5bMD52DIS_PPGFARMACOLOGIA_2008_CRUZ_FERNANDO.pdf.txtDIS_PPGFARMACOLOGIA_2008_CRUZ_FERNANDO.pdf.txtExtracted texttext/plain126181http://repositorio.ufsm.br/bitstream/1/8938/4/DIS_PPGFARMACOLOGIA_2008_CRUZ_FERNANDO.pdf.txtc079ba0edf55cd3487bf2dd8cb441a5bMD54THUMBNAILFERNANDOSILVERIOFERREIRADACRUZ.pdf.jpgFERNANDOSILVERIOFERREIRADACRUZ.pdf.jpgIM Thumbnailimage/jpeg4958http://repositorio.ufsm.br/bitstream/1/8938/3/FERNANDOSILVERIOFERREIRADACRUZ.pdf.jpgcb148c0b9b3c781472aa1c40a1bb1c68MD53DIS_PPGFARMACOLOGIA_2008_CRUZ_FERNANDO.pdf.jpgDIS_PPGFARMACOLOGIA_2008_CRUZ_FERNANDO.pdf.jpgIM Thumbnailimage/jpeg4958http://repositorio.ufsm.br/bitstream/1/8938/5/DIS_PPGFARMACOLOGIA_2008_CRUZ_FERNANDO.pdf.jpgcb148c0b9b3c781472aa1c40a1bb1c68MD551/89382023-04-20 10:16:40.361oai:repositorio.ufsm.br:1/8938Biblioteca Digital de Teses e Dissertaçõeshttps://repositorio.ufsm.br/ONGhttps://repositorio.ufsm.br/oai/requestatendimento.sib@ufsm.br||tedebc@gmail.comopendoar:2023-04-20T13:16:40Biblioteca Digital de Teses e Dissertações do UFSM - Universidade Federal de Santa Maria (UFSM)false
dc.title.por.fl_str_mv Alterações fisiológicas e efeitos sedativos da associação entre buprenorfina e xilazina em equinos
dc.title.alternative.eng.fl_str_mv Physiological changes and sedative effects of the association between buprenorphine and xylazine in horses
title Alterações fisiológicas e efeitos sedativos da associação entre buprenorfina e xilazina em equinos
spellingShingle Alterações fisiológicas e efeitos sedativos da associação entre buprenorfina e xilazina em equinos
Cruz, Fernando Silvério Ferreira da
Xilazina
Buprenorfina
Equinos
Sedação
Analgesia
Xylazine
Buprenorphine
Horses
Sedation
Analgesia
CNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIA
title_short Alterações fisiológicas e efeitos sedativos da associação entre buprenorfina e xilazina em equinos
title_full Alterações fisiológicas e efeitos sedativos da associação entre buprenorfina e xilazina em equinos
title_fullStr Alterações fisiológicas e efeitos sedativos da associação entre buprenorfina e xilazina em equinos
title_full_unstemmed Alterações fisiológicas e efeitos sedativos da associação entre buprenorfina e xilazina em equinos
title_sort Alterações fisiológicas e efeitos sedativos da associação entre buprenorfina e xilazina em equinos
author Cruz, Fernando Silvério Ferreira da
author_facet Cruz, Fernando Silvério Ferreira da
author_role author
dc.contributor.advisor1.fl_str_mv Carregaro, Adriano Bonfim
dc.contributor.advisor1Lattes.fl_str_mv http://lattes.cnpq.br/5041153897534751
dc.contributor.referee1.fl_str_mv Corte, Flavio Desessards de La
dc.contributor.referee1Lattes.fl_str_mv http://lattes.cnpq.br/4040388452531898
dc.contributor.referee2.fl_str_mv Queiroz Neto, Antonio de
dc.contributor.referee2Lattes.fl_str_mv http://lattes.cnpq.br/6695662273447490
dc.contributor.authorLattes.fl_str_mv http://lattes.cnpq.br/4262392857518163
dc.contributor.author.fl_str_mv Cruz, Fernando Silvério Ferreira da
contributor_str_mv Carregaro, Adriano Bonfim
Corte, Flavio Desessards de La
Queiroz Neto, Antonio de
dc.subject.por.fl_str_mv Xilazina
Buprenorfina
Equinos
Sedação
Analgesia
topic Xilazina
Buprenorfina
Equinos
Sedação
Analgesia
Xylazine
Buprenorphine
Horses
Sedation
Analgesia
CNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIA
dc.subject.eng.fl_str_mv Xylazine
Buprenorphine
Horses
Sedation
Analgesia
dc.subject.cnpq.fl_str_mv CNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIA
description The α₂-adrenergic receptor agonists are widely used in equine practice, especially in antalgic therapy, because they promote profound sedation and moderate visceral analgesia. The opioids are used in horses with some restriction due to the excitatory effects in this specie. The objective of this study was to evaluate the sedative effect, hemodynamic, pulmonary and digestory changes due to the neuroleptoanalgesic association of buprenorphine and different doses of xylazine. Six adults horses of both gender, weighting an average of 400 Kg. The animals were control of themselves, being divided into four groups, control group (CG) saline NaCl 0,9% solution administrated IV, and three other groups with buprenorphine 10 μg/kg associated to three different doses of xylazine, 0,25 mg/kg (BX25), 0,50 mg/kg (BX50) and 0,75 mg/kg (BX75) IV. Sedative effects, gastrointestinal motility, FC, f, SAP, MAP, DAP, blood gas tension analysis and core temperature were evaluated 30 min before, immediately before the administration of any treatment for basal values and after 5, 15 and every 15 min until 120 min post-treatment. Gastrointestinal motility was evaluated by the same period and for 12 hours, every 2 hours. Blood samples were collected at 0, 30 and 60 min. Parametric variables were analyzed with ANOVA, followed by Dunnett test for intra group and Tukey test between groups. For the non-parametric variable (intestinal motility) Wilcoxon test was used. Differences was considered significant when P<0.05. Intense sedative effect was observed in the three groups with the neuroleptoanalgesic association lasting 45 min in BX75 with profound ataxia. Intestinal motility decreased with 5 minutes after administration and remained decreased for 8 hours. Hemodynamic parameters started to increased after 30 min and no changes were observed in respiratory frequency and blood gas samples analysis, only HCO3- showed increase. Synergistic effect was observed, maintaining hemodynamic stability, with minimal pulmonary effects. The hypomotility observed must be considered when the association is used in horses with gastrointestinal disorders.
publishDate 2008
dc.date.issued.fl_str_mv 2008-08-08
dc.date.accessioned.fl_str_mv 2009-03-09
dc.date.available.fl_str_mv 2009-03-09
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.citation.fl_str_mv CRUZ, Fernando Silvério Ferreira da. Physiological changes and sedative effects of the association between buprenorphine and xylazine in horses. 2008. 78 f. Dissertação (Mestrado em Farmácia) - Universidade Federal de Santa Maria, Santa Maria, 2008.
dc.identifier.uri.fl_str_mv http://repositorio.ufsm.br/handle/1/8938
identifier_str_mv CRUZ, Fernando Silvério Ferreira da. Physiological changes and sedative effects of the association between buprenorphine and xylazine in horses. 2008. 78 f. Dissertação (Mestrado em Farmácia) - Universidade Federal de Santa Maria, Santa Maria, 2008.
url http://repositorio.ufsm.br/handle/1/8938
dc.language.iso.fl_str_mv por
language por
dc.relation.cnpq.fl_str_mv 201000000000
dc.relation.confidence.fl_str_mv 400
500
300
500
300
dc.relation.authority.fl_str_mv a0421801-2f7d-45b2-a7fb-c0b089433af7
e3ab06bd-3d28-4b33-a997-93ba02edaec5
ab8aec2d-f3fe-45a4-8bc3-07256644578f
19e8f84b-7ad7-4606-973b-baf5993524db
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade Federal de Santa Maria
dc.publisher.program.fl_str_mv Programa de Pós-Graduação em Farmacologia
dc.publisher.initials.fl_str_mv UFSM
dc.publisher.country.fl_str_mv BR
dc.publisher.department.fl_str_mv Farmacologia
publisher.none.fl_str_mv Universidade Federal de Santa Maria
dc.source.none.fl_str_mv reponame:Biblioteca Digital de Teses e Dissertações do UFSM
instname:Universidade Federal de Santa Maria (UFSM)
instacron:UFSM
instname_str Universidade Federal de Santa Maria (UFSM)
instacron_str UFSM
institution UFSM
reponame_str Biblioteca Digital de Teses e Dissertações do UFSM
collection Biblioteca Digital de Teses e Dissertações do UFSM
bitstream.url.fl_str_mv http://repositorio.ufsm.br/bitstream/1/8938/1/DIS_PPGFARMACOLOGIA_2008_CRUZ_FERNANDO.pdf
http://repositorio.ufsm.br/bitstream/1/8938/2/FERNANDOSILVERIOFERREIRADACRUZ.pdf.txt
http://repositorio.ufsm.br/bitstream/1/8938/4/DIS_PPGFARMACOLOGIA_2008_CRUZ_FERNANDO.pdf.txt
http://repositorio.ufsm.br/bitstream/1/8938/3/FERNANDOSILVERIOFERREIRADACRUZ.pdf.jpg
http://repositorio.ufsm.br/bitstream/1/8938/5/DIS_PPGFARMACOLOGIA_2008_CRUZ_FERNANDO.pdf.jpg
bitstream.checksum.fl_str_mv 3e604c1ba91c9deddf24078cec533efa
c079ba0edf55cd3487bf2dd8cb441a5b
c079ba0edf55cd3487bf2dd8cb441a5b
cb148c0b9b3c781472aa1c40a1bb1c68
cb148c0b9b3c781472aa1c40a1bb1c68
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Biblioteca Digital de Teses e Dissertações do UFSM - Universidade Federal de Santa Maria (UFSM)
repository.mail.fl_str_mv atendimento.sib@ufsm.br||tedebc@gmail.com
_version_ 1801485312149422080